A detailed history of Tang Capital Management LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Tang Capital Management LLC holds 50,825 shares of RLMD stock, worth $18,297. This represents 0.01% of its overall portfolio holdings.

Number of Shares
50,825
Previous 237,874 78.63%
Holding current value
$18,297
Previous $713,000 77.0%
% of portfolio
0.01%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $4.36 $430,212 - $815,533
-187,049 Reduced 78.63%
50,825 $164,000
Q2 2024

Aug 14, 2024

BUY
$2.93 - $4.94 $695,851 - $1.17 Million
237,492 Added 62170.68%
237,874 $713,000
Q1 2024

May 15, 2024

BUY
$3.1 - $6.8 $1,184 - $2,597
382 New
382 $1,000
Q4 2022

Feb 14, 2023

SELL
$2.17 - $35.84 $651,000 - $10.8 Million
-300,000 Reduced 75.0%
100,000 $349,000
Q2 2022

Aug 15, 2022

BUY
$16.5 - $30.34 $6.6 Million - $12.1 Million
400,000 New
400,000 $7.6 Million
Q1 2022

May 16, 2022

SELL
$16.72 - $26.99 $988,519 - $1.6 Million
-59,122 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$16.93 - $26.82 $692,064 - $1.1 Million
-40,878 Reduced 40.88%
59,122 $1.33 Million
Q2 2021

Aug 16, 2021

SELL
$29.55 - $39.15 $2.96 Million - $3.92 Million
-100,000 Reduced 50.0%
100,000 $3.2 Million
Q4 2020

Feb 16, 2021

SELL
$29.88 - $39.8 $8.96 Million - $11.9 Million
-300,000 Reduced 60.0%
200,000 $6.41 Million
Q2 2020

Aug 14, 2020

SELL
$31.59 - $49.98 $25.3 Million - $40 Million
-800,000 Reduced 61.54%
500,000 $22.4 Million
Q4 2019

Feb 14, 2020

BUY
$10.1 - $47.18 $13.1 Million - $61.3 Million
1,300,000 New
1,300,000 $50.7 Million

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.3M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Tang Capital Management LLC Portfolio

Follow Tang Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tang Capital Management LLC with notifications on news.